Article
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Nature genetics - 1 Jun 2020
Jiménez-Sánchez Alejandro, Cybulska Paulina, Mager Katherine LaVigne, Koplev Simon, Cast Oliver, Couturier Dominique-Laurent, Memon Danish, Selenica Pier, Nikolovski Ines, Mazaheri Yousef, Bykov Yonina, Geyer Felipe C, Macintyre Geoff, Gavarró Lena Morrill, Drews Ruben M, Gill Michael B, Papanastasiou Anastasios D, Sosa Ramon E, Soslow Robert A, Walther Tyler, Shen Ronglai, Chi Dennis S, Park Kay J, Hollmann Travis, Reis-Filho Jorge S, Markowetz Florian, Beltrao Pedro, Vargas Hebert Alberto, Zamarin Dmitriy, Brenton James D, Snyder Alexandra, Weigelt Britta, Sala Evis, Miller Martin L
Abstract excerpt
In metastatic cancer, the degree of heterogeneity of the tumor microenvironment (TME) and its molecular underpinnings remain largely unstudied. To characterize the tumor-immune interface at baseline and during neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC), we performed immunogenomic analysis of treatment-naive and paired samples from before and after treatment with chemotherapy. In...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
